Trial Profile

A Randomized, Blinded, Placebo-Controlled, Phase 1 Single Ascending Dose Study in Healthy Adult Male Volunteers and an Open-Label Multiple Ascending Dose Study in Pediatric SMA Participants Previously Treated With Onasemnogene Abeparvovec (Zolgensma) to Evaluate the Safety, Tolerability, and Pharmacokinetics of BIIB115

Status: Active, no longer recruiting

Phase of Trial: Phase I

Latest Information Update: 02 Jul 2025

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

25 Jun 2025 According to Biogen media release, Based on results from Phase 1 trial, the company is planning for Registrational trials for Spinal Muscular Atrophy.
25 Jun 2025 According to Biogen media release, data from this trial,presented today at the SMA Research & Clinical Care Meeting hosted by Cure SMA in Anaheim, Calif.
25 Jun 2025 Topline Results presented the Biogen Media Release

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com